## Please fax all pages of completed form to your team at 888.302.1028. To reach your team, call toll-free 844.516.3319.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

**Prescription & Enrollment Form Nulojix**®



## Four simple steps to submit your referral.

| 1 Patient Informa   | ntion                      |                   |                      | de copies of front and back of all medical otion insurance cards.                                  |
|---|----------------------------|-------------------|----------------------|--|
| New patient Current patier                                  | nt                         |                   |                      |  |
| Patient's first name  |                            | Last na           | me                   | Middle initial   |
| Preferred patient first name                                |                            |                   | Preferred patient    | t last name  |
| Sex at birth: Male Female                                   | Gender identity            | Prono             | ouns                 | Last 4 digits of SSN   |
| Date of birthS  | Street address             |                   |                      | Apt #  |
| City  |                            | _ State           |                      | Zip  |
| Home phone  | Cell phone                 |                   | Email a              | address  |
| Parent/guardian (if applicable)                             |                            |                   |                      |  |
| Home phone  | Cell phone                 |                   | Email a              | address  |
| Alternate caregiver/contact                                 |                            |                   |                      |  |
| Home phone  | Cell phone                 |                   | Email a              | address  |
| OK to leave message with altern                             | nate caregiver/contact     |                   |                      |  |
| artificial voice calls, emails and/or tex frequency varies. | t messages from Accredo ab | out your prescrip | tion(s), account, an | ddress above, you consent to receiving automated/d health care. Standard data rates apply. Message |
| 2 Prescriber Info   | rmation                    | All               | fields must be co    | empleted to expedite prescription fulfillment.   |
| Date  | Time                       | Dat               | e medication nee     | ded  |
| Office/clinic/institution name                              |                            |                   |                      |  |
| Prescriber info: Prescriber's first n                       | ame                        |                   | Last r               | name   |
| Prescriber's title  |                            | If NP or          | PA, under direction  | on of Dr   |
| Office phone  | Fax                        | N                 | PI #                 | License #  |
| Office contact and title                                    |                            |                   | Office of            | contact email  |
|   |                            |                   |                      | Suite #  |
|   |                            |                   |                      | Zip  |
| Infusion location: Patient's home                           |                            | Infusion site If  |                      | pplete information below dotted line:  |
| Infusion info: Infusion site name                           |                            |                   | Clinic/hospital at   | filiation  |
|   |                            |                   | ·                    | Suite #  |
|   |                            |                   |                      | Zip  |
| •   |                            |                   |                      | •  |
| 3 Clinical Informa  |                            |                   | Fax                  | Email  |
| Primary ICD-10 code (REQUIRED)                              | :                          | Has the           | e patient been tre   | ated previously for this condition? Yes No   |
| Is patient currently on therapy?                            | Yes No Please list all     | therapies tried/  | failed:              |  |
| Patient wtNKDA Known drug allergies                         |                            |                   |                      |  |
| Concurrent meds   |                            |                   |                      |  |

| Patient's first name    | Last name | Middle initial | Date of birth |  |
|-------------------------|-----------|----------------|---------------|--|
| Prescriber's first name | Last name | Phone          |               |  |
|                         |           |                |               |  |

## 4

## **Prescribing Information**

INFUSION LOCATION: Patient's home Healthcare facility

| Medication           | Strength/Formulation   | Directions  | Quantity/Refills  | Ship to  |
|----------------------|--|---|---|--|
| Nulojix <sup>®</sup> | The total infusion dose of Nulojix should be based on the actual body weight of the patient at the time of transplantation and should not be modified during the course of therapy, unless there is a change in body weight of greater than 10%. Date of Transplant:  Weight at time of transplant:  Current Weight: | Initial Phase Dosing (post-transplant): Infuse 10mg/kg (mg) intravenously at the end of weeks 2, 4, 8, 12.  Patient does not need initial phase dosing  If patient needs partial initial phase dosing, indicate what is needed:  End of weeks 4, 8, 12  End of weeks 8, 12  End of week 12 only  OR  Alternate Initial Phase Dosing (post-transplant): Infusemg/kg (mg) intravenously every weeks for a total of doses to complete the initial phase.  Clinical Rationale for alternate dosing: | Dispense: QS for initial phase dosing No Refills Other Qty Other Refills                | The initial phase dosing must be administered in a controlled setting.  Please check one:  MDO Infusion Clinic Unknown |
|                      |  | Maintenance Phase Dosing (post-transplant): Infuse 5mg/kg (mg) intravenously at the end of week 16 and every 4 weeks thereafter.  OR  Alternate Maintenance Phase Dosing (post-transplant): Infusemg/kg (mg) intravenously every weeks.  Clinical Rationale for alternate dosing:   | Dispense: 28-day supply Refill x 1 year unless noted otherwise. Other Qty Other Refills | Please check one: Home MDO Infusion Clinic Unknown   |

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication. If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

| SIGN | ı |
|------|---|
| HERE |   |

| Date | Dispense as written | Date | Substitution allowed |
|------|---------------------|------|----------------------|

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

| Patient's first name                                 | Last name  | Middle initia              | l Date of birth                                     |
|--|--|----------------------------|---|
| Prescriber's first name                              | Last name  |                            | _ Phone   |
| 4 Prescribing Infor                                  |  |                            |   |
|  | for home infusion (please complete this  | section for home infusions | <u> </u>  |
| Premedication orders:                                |  |                            | Send quantity and refills sufficient for medication |
| Infusion method: Gravity unless otherwi              | ise instructed ( Prefer Pump)  |                            | dosing and days supply.                             |
|  | ution (please strike through if not required)  |                            |   |
| NS 0.9% 100mL  |  |                            |   |
| NS 0.9% Flush (if central venous acces               | ss, sterile flush will be provided)  |                            |   |
| All Nulojix orders will be administered v            | via peripheral line unless otherwise noted.  |                            |   |
| Choose administration access: Perip                  | heral access Central venous access   |                            |   |
| If central venous access: Flush with 10              | mL Sterile NS 0.9% before and after infusion.  | Follow with heparin 100un  | its/mL 5mL  |
| final flush  |  |                            |   |
| If peripheral access: Flush with 3mL N               | S 0.9% before and after infusion and as needed   | <u>I</u>                   |   |
| <b>Hypersensitivity/Anaphylaxis</b><br>Stop infusion |  |                            |   |
| Medicate with:                                       | and four assembly desire   |                            |   |
| Epinephrine/EpiPen 0.3mg IM as neede                 | . ,  |                            |   |
| Diphenhydramine 50mg PO PRN an                       |  |                            |   |
| Other  |  |                            |   |
| <u> </u>   | tablish venous access, administer medication a tration, the home health nurse will call for addit        | _                          | · · · · · · · · · · · · · · · · · · ·               |
|  | ies and home medical equipment necessary to adr<br>accepts on behalf of patient for administration in of |                            |   |
| Prescriber's signature required (sign                | below) (Physician attests this is his/her le   | gal signature. NO STAMPS   | <b>(i)</b>  |
| IGN  | -  |                            |   |
| ERE /  |  |                            |   |

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

